Lives unaffected by cystic fibrosis

Clinical Trial Finder

Be a part of the movement transforming the future of cystic fibrosis treatment.

Clinical trials are listed below.

  • BehavioralEnrolling Location: USA

    Phase 4 study of adherence to lumacaftor/ivacaftor in people with CF , protocol number Vertex VX-809-114

    This study is taking place at multiple care centres across the US. It will look at the impact of using a smart device that monitors medication use on adherence to lumacaftor/ivacaftor.

    • Age:

      16 Years and Older

    • Mutation(s):

      Two Copies F508del

    • FEV1% Predicted:

      40% or greater

    • Number of Visits:

      7

    • Length of Participation:

      48 weeks

    Contact us about this clinical Trial >
  • Restore CFTR FunctionEnrolling Location: Multiple US sites

    Phase 2 study of CTP-656 in aduts with CF who are currently taking ivacaftor (Kalydeco) , protocol number NCT02971839 CP656.2001

    This study will evaluate the safety and effectiveness of the drug, CTP-656 in adults with Cystic Fibrosis who have a gating mutation and are currently taking ivacaftor (KALYDECO)

    • Age:

      18 years and older

    • Mutation(s):

      One copy F508del or no copies F508del

    • FEV1% Predicted:

      60-90%

    • Number of Visits:

      6

    • Length of Participation:

      7 weeks

    Contact us about this clinical Trial >
  • Restore CFTR FunctionEnrolling Location: Multiple care centres across the US

    RESTORE-CF: Phase 1/2 study of MRT5005 in adults with cystic fibrosis (Parts A & B) , protocol number NCT03375047 -Translate Bio RESTORE-CF MRT5005-101

    This first human study is taking place at multiple care centers across the US. It will look at the safety and tolerability of different doses of the nebulized drug MRT5005 in adults with CF.

    • Age:

      18 years and older

    • Mutation(s):

      No mutation requirement

    • FEV1% Predicted:

      50-90%

    • Number of Visits:

      21

    • Length of Participation:

      12 months

    Contact us about this clinical Trial >
  • Restore CFTR FunctionEnrolling Location: Multiple care centres across the US

    Phase 3 study of VX-445 triple combination drug in people with CF 12 years and older who have one copy of the F508del mutation and one copy of a minimal function mutation (Vertex VX17-445-102) , protocol number NCT03525444 VX17-445-102

    This randomized, placebo-controlled study will be taking place at multiple care centers across the U.S. It will evaluate the effectiveness, safety, and effect on the body of the drug VX-445 in combination with tezacaftor and ivacaftor. It is for people with cystic fibrosis ages 12 and older with one copy of the F508del CFTR mutation and one copy of a minimal function mutation.

    • Age:

      12 years and older

    • Mutation(s):

      One copy F508del

    • FEV1% Predicted:

      40-90%

    • Number of Visits:

      10

    • Length of Participation:

      32 weeks

    Contact us about this clinical Trial >
  • Restore CFTR FunctionEnrolling Location: Multiple care centres across the US

    Phase 3 study of VX-445 triple combination drug in people with CF ages 12 years and older who have two copies of the F508del mutation (Vertex VX17-445-103) , protocol number NCT03525548 VX17-445-103

    This randomized, controlled study is taking place at multiple care centers across the U.S. It will look at the effectiveness and safety of the drug VX-445 in combination with ivacaftor and tezacaftor. It is for people with CF ages 12 and older who have two copies of the F508del CFTR mutation.

    • Age:

      12 years and older

    • Mutation(s):

      Two copies of F508del

    • FEV1% Predicted:

      40 - 90%

    • Number of Visits:

      7

    • Length of Participation:

      10 weeks

    Contact us about this clinical Trial >
  • Displaying results 161-165 (of 165)
     |<  <  8 - 9 - 10 - 11 - 12 - 13 - 14 - 15 - 16 - 17 >  >|